Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom

NCT04583995 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT04583995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04583995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom
Lead sponsor
Novavax
Phase
Phase 3
Overall status
Completed
Start date
September 28, 2020
Completion date
March 29, 2022
Enrollment
15,185 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection